BVNRY BAVARIAN NORDIC
-
BAVARIAN NORDIC Reported Earnings
Wednesday, May 13, 2026 · 12:00 AM ET
BAVARIAN NORDIC (BVNRY) reported earnings of $0.01 per share on revenue of $165.70 million for the . . Revenue fell 12.74% compared to the same quarter a year ago.
Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company's product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
$0.01
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth
Reported Revenue
$165.70M
Revenue Estimate
—
Revenue Surprise
Revenue Growth